Your browser doesn't support javascript.
loading
[Evaluation of glucose metabolism in acromegalic patients before and after treatment with octreotide LAR]. / Avaliação do metabolismo da glicose em pacientes acromegálicos antes e após tratamento com octreotide LAR.
Correa, Lívia L; Taboada, Giselle F; Van Haute, Flávia R; Casini, Alessandra F; Balarini, Giovanna A; Vieira Neto, Leonardo; Machado, Evelyn de O; Fontes, Rosita; Andrade, Cláudia C de; Schrank, Yolanda; Gadelha, Mônica R.
Afiliación
  • Correa LL; Serviço de Endocrinologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, RJ, Brazil.
Arq Bras Endocrinol Metabol ; 52(1): 55-64, 2008 Feb.
Article en Pt | MEDLINE | ID: mdl-18345397
AIM OF THE STUDY: To evaluate the glucose metabolism in acromegalic patients before and after treatment with octreotide LAR. PATIENTS AND METHODS: This was a prospective and longitudinal study involving 30 patients from the acromegaly research outpatient clinic of the Endocrinology unit of the HUCFF/UFRJ. They underwent clinical and laboratorial evaluations, with measurements of growth hormone (GH), insulin-like growth factor type I (IGF-I), insulin, proinsulin, C peptide, glycosylated hemoglobin (HbA1c), IGF binding protein type 1 (IGFBP-1) and glucose, during oral glucose tolerance test (OGTT), before and after six months of treatment with octreotide LAR. The Wilcoxon signed-rank test was used and values of 5% were considered statistically significant. RESULTS: We found 16 (54%) patients with normal glucose tolerance, 7 (23%) with impaired glucose tolerance and 7 (23%) diabetics. Twelve patients completed the six-month treatment, out of which three showed worsening of glucose tolerance and two (diabetics) had worse blood glucose control. Whereas there was an increase in waist circumference (p=0.03), there was a decrease in GH (p=0.04), with %IGF-I above the upper limit of reference values (% ULRV) [p=0.001], insulin (p=0.019), C peptide levels (p=0.002) and homeostatic model assessment (HOMA-IR) [p=0.039]. CONCLUSIONS: In this series, treatment with octreotide LAR led to a worsening of glucose tolerance in three non-diabetic patients and worsened glycemic control in two diabetics, in spite of reducing insulin resistance.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Acromegalia / Octreótido / Intolerancia a la Glucosa / Antineoplásicos Hormonales / Hormona de Crecimiento Humana / Glucosa Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male Idioma: Pt Revista: Arq Bras Endocrinol Metabol Año: 2008 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Brasil
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Acromegalia / Octreótido / Intolerancia a la Glucosa / Antineoplásicos Hormonales / Hormona de Crecimiento Humana / Glucosa Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male Idioma: Pt Revista: Arq Bras Endocrinol Metabol Año: 2008 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Brasil